{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "SLN",
  "name": "Silence Therapeutics Plc",
  "url": "https://frontierpicks.com/dossiers/SLN/",
  "json_url": "https://frontierpicks.com/dossiers/SLN.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "First-in-class siRNA re-rated on the 2026-08-10 SANRECO readout (88% response vs 19% placebo, n=48) and immediately funded with a ~$175M raise priced at $13.50/ADS; with Phase 3 not starting until 1H 2027, the equity now trades on zerlasiran partnering language and three September fireside chats rather than new data, leaving a maturing narrative with no company-dated clinical catalyst.",
  "invalidation_trigger": "A weekly close below $13.50 — the 2026-08-11 offering price at which 12,962,963 ADSs were placed — breaks the post-readout shelf. Secondary: the 09-09/09-15/09-16 conference block passing with zerlasiran partnering language unchanged, leaving nothing company-dated before the 1H 2027 Phase 3 start.",
  "catalyst_date": "2026-09-09",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "rare-disease-gene-therapy",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "US-listed instrument is an ADS of a UK-incorporated plc; ADS economics depend on the deposit ratio and depositary fees, which differ from holding the ordinary shares.",
    "Clinical-stage developer with no approved product and no product revenue; operating cash comes from equity issuance and partner payments.",
    "No company-dated clinical readout is scheduled between 2026-09-05 and the guided 1H 2027 Phase 3 start; interim news flow is conference and partnering commentary.",
    "Zerlasiran Phase 3 timing is explicitly contingent on a third-party partner, so that program's value is event-driven rather than calendar-driven."
  ],
  "body_markdown": "\n> Research note. Not investment advice. All levels are analysis of public market data.\n\n## SLN — Silence Therapeutics plc\n\n## Current Thesis\n\nSilence is a clinical-stage siRNA developer whose equity re-rated in one session on 2026-08-10, when the Phase 2 SANRECO trial of divesiran in polycythemia vera met its primary endpoint — 88% clinical response versus 19% for placebo in 48 phlebotomy-dependent patients, with 93.8% at the every-6-week interval and 81.3% at every-12-week. The ADSs rose 34.3% that session and printed a 52-week high of $15.43. Management put the funding question to bed inside 48 hours: an offering announced at roughly $150M on 2026-08-10 was upsized and priced at $13.50 per ADS for 12,962,963 ADSs (~$175M gross), closing 2026-08-14.\n\nWhat an investor is buying now is the gap between a de-risked hematology asset and a Phase 3 that does not start until 1H 2027, bridged by a second Phase 3-ready asset — zerlasiran for Lp(a)-driven cardiovascular disease — whose trial initiation the company has stated depends on finding a third-party partner. The narrative is maturing: the readout is three and a half weeks old, Morgan Stanley already marked to it on 2026-08-11 (Overweight, target raised to $32 from $25), and the company has produced no news since the offering closed on 2026-08-14 other than a conference schedule. The shares closed at $14.59 on 2026-09-04, 5.4% under the high, with RSI(14) at 53.4 — the August surge has been digested without being extended.\n\n## Bull Case\n\n- **The primary endpoint was not marginal.** 88% versus 19% on placebo, both dose arms positive (93.8% Q6W, 81.3% Q12W), n=48, reported 2026-08-10. BioSpace's 2026-08 coverage framed the result as setting a high bar for competitors in the space.\n- **Phase 3 will test the least frequent schedule the program has run** — every 12 weeks — with a start guided to 1H 2027. A quarterly subcutaneous dosing interval in a chronic phlebotomy-dependent population is the commercial argument, and the Q12W arm cleared the endpoint at 81.3%.\n- **The financing overhang was cleared on the news, not after it.** $72.1M cash at 2026-06-30 was augmented by ~$175M gross priced at $13.50 per ADS and closed 2026-08-14 — a raise larger than the entire pre-deal cash balance, into strength rather than into a drawdown.\n- **The cost base already contracted.** Q2 2026 R&D of $9.1M against $17.6M in Q2 2025; net loss $12.3M ($0.09 per share) against $27.4M ($0.19), beating the $(0.15) consensus, all reported 2026-08-10. The decline reflects zerlasiran Phase 3 readiness having been completed in 2025.\n- **A second asset carries no incremental spend.** Zerlasiran is described by the company as Phase 3-ready with core readiness activities complete; a partnership would convert a sunk cost into an economic interest without Silence funding the trial.\n- **Pipeline optionality is dated, not vague.** SLN312 (AZD1705, ANGPTL3) Phase 1 data were presented at the European Atherosclerosis Society Congress in May 2026 showing dose-dependent, durable ANGPTL3 reductions; SLN098 (INHBE) preclinical obesity data support a potential IND in 2027.\n\n## Bear Case\n\n- **The re-rating catalyst has already fired.** The next company-dated clinical event is a Phase 3 start in 1H 2027. Between 2026-09-05 and that window there is no scheduled readout — three September fireside chats are attention, not data.\n- **Supply was manufactured at $13.50.** 12,962,963 ADSs were created at that level on the pricing, closing 2026-08-14. That block sits immediately beneath the 2026-09-04 close of $14.59 and defines where the post-readout shelf gives way.\n- **Topline is not the dataset.** As of 2026-09-04 no full SANRECO presentation at a medical meeting has been dated — durability, hematocrit control over time and the full safety table remain unpublished.\n- **Zerlasiran's timeline belongs to someone else.** The Q2 2026 business update conditions Phase 3 initiation on a third-party partner. A partnership has no announced date and no announced counterparty.\n- **Single-asset concentration.** Divesiran carries the equity story; an FDA interaction that changes the Phase 3 design, endpoint or size would hit the whole valuation, and the company has no approved product and no product revenue to cushion it.\n- **The bid has not widened since the print.** The name appeared on retail mover lists on 2026-08-10 and again on 2026-09-04, but the tape between 2026-08-12 and 2026-09-04 held a range rather than making a new high.\n\n## Setup & Price Structure\n\nThe reference close is $14.59 on 2026-09-04, 5.4% below the 52-week high of $15.43, with a three-month price change of +134.2% and RSI(14) at 53.4. That combination describes digestion: a doubled stock that has neither given back the gap nor pushed through the high, sitting at a neutral momentum reading roughly three weeks after the event that created it.\n\nThe structurally important level is $13.50 — the 2026-08-11 offering price at which nearly 13 million ADSs were placed. Above it, every buyer from the deal is whole and the post-readout base holds. A weekly close beneath it puts the entire tranche underwater and removes the shelf the August gap has been resting on. On the upside, a weekly close above $15.43 would take out the high set on 2026-08-10 and mark the first genuine expansion of the range since the print.\n\nCrowding and positioning observables, stated as observables: the issuer itself sold equity into the move and upsized the deal from roughly $150M to $175M; the sell-side target revision (Morgan Stanley, $32 from $25) landed the day after the data, so the analyst mark-up is already in the record rather than pending; stockanalysis.com's aggregation of seven analysts polled by S&P Global showed a consensus target of $29.17 when retrieved on 2026-09-05, and target dispersion across aggregators is wide enough that no single consensus figure should be treated as the market's. No insider sale has surfaced in the news and filing record reviewed through 2026-09-04 — the dilution in this name came from the company, not from officers. Three investor conferences inside eight days (09-09, 09-15, 09-16) concentrate management commentary into a short window with no new dataset behind it.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-09** — Cantor Global Healthcare Conference fireside chat, 10:55 a.m. ET. First scheduled management appearance since the offering closed on 2026-08-14.\n- **2026-09-15** — H.C. Wainwright 28th Annual Global Investment Conference fireside chat, 3:00 p.m. ET.\n- **2026-09-16** — Morgan Stanley 24th Annual Global Healthcare Conference fireside chat, 8:30 a.m. ET. Morgan Stanley is the house that raised its target to $32 on 2026-08-11.\n- **~2026-11-09 (est.)** — Q3 2026 results. Outside the 30-day window; Q2 was reported 2026-08-10.\n\n## Elapsed catalysts\n\n- **Undated, live** — a zerlasiran partnership announcement. The company has stated Phase 3 timing depends on it; no date or counterparty has been disclosed as of 2026-09-04. *(passed 2d ago)*\n- **Undated, live** — full SANRECO Phase 2 data at a medical meeting. No presentation date announced as of 2026-09-04. *(passed 2d ago)*\n\n## What Would Change Our Mind\n\nThe August gap rests on a single topline dataset and a single financing, and the level where that structure fails is the price at which the financing was placed. A weekly close below $13.50 — the 2026-08-11 offering price for 12,962,963 ADSs — would put the entire post-readout placement underwater and end the post-data base as a working structure.\n\nThree secondary conditions would each degrade the case independently of price. First, the September conference block (09-09, 09-15, 09-16) passing with no change in the zerlasiran partnering language would confirm that the second asset has no timeline, leaving nothing company-dated before the 1H 2027 Phase 3 start. Second, a full SANRECO presentation that shows durability falling off between the 6-week and 12-week arms, or a safety signal not visible in the topline, would undercut the Q12W-interval argument that the Phase 3 design rests on. Third, a fresh equity issuance or ATM usage within two quarters of a $175M raise would argue the funded-into-2028 framing is thinner than presented.\n\nOn the other side, a weekly close above $15.43 with a named zerlasiran partner would extend the leg and give the story a second dated asset rather than one.\n\n## Correlation Notes\n\nNo published theme cluster currently carries this name, so the thesis does not lean on a group move — it is a single-name clinical story. The observable supporting that: the 2026-08-10 session in which SLN rose 34.3% saw the healthcare mover lists populated by unrelated small caps (BWMN +55.1%, HZO +45.8%, ABCL +35.6%), with no PV or siRNA peer moving in sympathy in that record.\n\nPractically, the residual correlations are three. Small- and mid-cap biotech beta (XBI-type risk appetite) sets the discount rate on an unprofitable developer whose nearest revenue is years out. Read-across from other RNAi and siRNA developers affects platform sentiment but not divesiran's data. And competitive news in polycythemia vera — any approval, label or Phase 3 result from a hepcidin-directed or interferon competitor — hits the addressable-market assumption directly, which matters because Silence's own Phase 3 does not begin until 1H 2027 and the field will not stand still during that gap.",
  "first_seen": "2026-09-03",
  "last_analyzed": "2026-09-06T08:07:55+00:00",
  "last_synthesized": "2026-09-05",
  "last_update_source": "research_universe",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}